Advances in predicting and manipulating the immunogenicity of biotherapeutics and vaccines

Darren R. Flower

Research output: Contribution to journalArticle

Abstract

Therapeutic proteins are vital to the future of human health provision and the survival and profitability of the global pharmaceutical industry. Returns from protein therapeutics are experiencing unprecedented growth: both their number and their economic dividend have increased by an order of magnitude in the last 10 years. The potential immunogenicity of protein therapeutics raises many clinical and safety concerns. Many poorly understood factors relating to both product and host affect immune responses. Available laboratory measurement of immunogenicity is of little utility for predicting the clinical properties of biotherapeutics. Coupled with assay variability and standardization issues, this precludes adequate prediction of the biological or clinical responses of therapeutic proteins, arguing for the utilization of informatic strategies in the analysis and prediction of protein immunogenicity. Currently, many unresolved issues must be addressed and thus circumvented before effective prediction can become routine.
Original languageEnglish
Pages (from-to)231-240
Number of pages10
JournalBioDrugs
Volume23
Issue number4
DOIs
Publication statusPublished - 1 Aug 2009

Fingerprint

Proteins
Informatics
Drug Industry
Therapeutics
Economics
Vaccine Immunogenicity
Safety
Survival
Health
Growth

Cite this

@article{6043cdcac1324bba9c407db9df3e0c2b,
title = "Advances in predicting and manipulating the immunogenicity of biotherapeutics and vaccines",
abstract = "Therapeutic proteins are vital to the future of human health provision and the survival and profitability of the global pharmaceutical industry. Returns from protein therapeutics are experiencing unprecedented growth: both their number and their economic dividend have increased by an order of magnitude in the last 10 years. The potential immunogenicity of protein therapeutics raises many clinical and safety concerns. Many poorly understood factors relating to both product and host affect immune responses. Available laboratory measurement of immunogenicity is of little utility for predicting the clinical properties of biotherapeutics. Coupled with assay variability and standardization issues, this precludes adequate prediction of the biological or clinical responses of therapeutic proteins, arguing for the utilization of informatic strategies in the analysis and prediction of protein immunogenicity. Currently, many unresolved issues must be addressed and thus circumvented before effective prediction can become routine.",
author = "Flower, {Darren R.}",
year = "2009",
month = "8",
day = "1",
doi = "10.2165/11317530-000000000-00000",
language = "English",
volume = "23",
pages = "231--240",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "4",

}

Advances in predicting and manipulating the immunogenicity of biotherapeutics and vaccines. / Flower, Darren R.

In: BioDrugs, Vol. 23, No. 4, 01.08.2009, p. 231-240.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advances in predicting and manipulating the immunogenicity of biotherapeutics and vaccines

AU - Flower, Darren R.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Therapeutic proteins are vital to the future of human health provision and the survival and profitability of the global pharmaceutical industry. Returns from protein therapeutics are experiencing unprecedented growth: both their number and their economic dividend have increased by an order of magnitude in the last 10 years. The potential immunogenicity of protein therapeutics raises many clinical and safety concerns. Many poorly understood factors relating to both product and host affect immune responses. Available laboratory measurement of immunogenicity is of little utility for predicting the clinical properties of biotherapeutics. Coupled with assay variability and standardization issues, this precludes adequate prediction of the biological or clinical responses of therapeutic proteins, arguing for the utilization of informatic strategies in the analysis and prediction of protein immunogenicity. Currently, many unresolved issues must be addressed and thus circumvented before effective prediction can become routine.

AB - Therapeutic proteins are vital to the future of human health provision and the survival and profitability of the global pharmaceutical industry. Returns from protein therapeutics are experiencing unprecedented growth: both their number and their economic dividend have increased by an order of magnitude in the last 10 years. The potential immunogenicity of protein therapeutics raises many clinical and safety concerns. Many poorly understood factors relating to both product and host affect immune responses. Available laboratory measurement of immunogenicity is of little utility for predicting the clinical properties of biotherapeutics. Coupled with assay variability and standardization issues, this precludes adequate prediction of the biological or clinical responses of therapeutic proteins, arguing for the utilization of informatic strategies in the analysis and prediction of protein immunogenicity. Currently, many unresolved issues must be addressed and thus circumvented before effective prediction can become routine.

UR - http://www.scopus.com/inward/record.url?scp=69249222717&partnerID=8YFLogxK

UR - https://link.springer.com/article/10.2165%2F11317530-000000000-00000

U2 - 10.2165/11317530-000000000-00000

DO - 10.2165/11317530-000000000-00000

M3 - Article

C2 - 19697965

VL - 23

SP - 231

EP - 240

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 4

ER -